NCT06151106View on ClinicalTrials.gov

Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

November 22, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 25, 2027

Conditions
Peripheral T Cell LymphomaRelapsed Peripheral T-Cell LymphomaRefractory T-Cell Lymphoma
Interventions
DRUG

Chidamide combined with Duvillisib

Specified dose on specified days

Trial Locations (1)

361000

RECRUITING

The First Affiliated Hosptial of Xiamen University, Xiamen

All Listed Sponsors
collaborator

Fujian Cancer Hospital

OTHER_GOV

collaborator

Zhangzhou Affiliated Hospital of Fujian Medical University

OTHER

collaborator

Dongguan People's Hospital

OTHER_GOV

collaborator

Huizhou Municipal Central Hospital

OTHER

collaborator

The First Affiliated Hospital with Nanjing Medical University

OTHER

collaborator

Sun Yat-sen University

OTHER

collaborator

Shanxi Province Cancer Hospital

OTHER

lead

The First Affiliated Hospital of Xiamen University

OTHER